비침습적, 비약물적 치료 기술에 대한 관심이 높아지면서 그 효과와 안전성에 대한 인식이 높아지면서 광생체 자극기에 대한 수요가 증가하고 있으며, Verified Market Research의 애널리스트에 따르면, 광생체 자극기 시장은 2023년 약 1억 9,582만 달러로 평가되었고, 예측 기간 동안 3억 1,364만 달러에 달할 것으로 추정됩니다.
시장은 의료 전문가와 소비자가 광생물 자극 요법의 이점을 인식함에 따라 속도를 높이고 있으며, 그 결과 다양한 의료 현장에서 이러한 장치의 사용이 증가하여 2024년부터 2031년까지 연평균 복합 성장률(CAGR) 6.07% 시장 성장을 가능하게 하고 있습니다.
저수준 레이저 치료(LLLT) 또는 콜드 레이저로도 알려진 광생체 자극기는 특정 파장의 빛을 사용하여 신체의 세포 과정을 활성화합니다. 이 장치는 비열적인 저강도 빛을 발생시켜 세포에 흡수되어 치유와 조직 재생을 촉진하는 다양한 생화학 반응을 일으킵니다. 요컨대, 광 바이오시뮬레이션은 빛의 치료 특성을 이용하여 신체에 해를 끼치지 않고 자연 치유 과정을 촉진하는 것입니다.
또한, 이러한 기기는 의료 및 미용의 다양한 분야에서 활용되고 있습니다. 의료 분야에서는 관절염, 건염, 스포츠 외상과 같은 질병으로 인한 통증을 조절하고 염증을 줄이고 근골격계 통증을 완화하는 데 사용됩니다. 광생체 자극기는 당뇨병성 궤양과 같은 급성 및 만성 상처의 조기 회복을 촉진하는 상처 치유에도 사용됩니다.
전 세계 인구는 신경병성 통증, 근골격계 질환, 관절염과 같은 만성 질환의 영향을 받고 있습니다. 이에 따라 다양한 상황에서 통증 관리, 염증 감소, 조직 치유를 촉진하는 데 도움이 되는 광생체자극장치에 대한 수요가 증가하고 있습니다.
통증 관리 및 재활을 위한 비침습적 방법은 의료 전문가와 환자들 사이에서 큰 지지를 받고 있습니다. 이러한 추세는 광생물학 시뮬레이션 치료의 효과와 안전성을 입증하는 임상적 증거 증가로 뒷받침되고 있으며, 이는 광생물학 시뮬레이션 치료의 채택 확대에 기여하고 있습니다.
또한, 레이저 및 LED 기술의 지속적인 발전으로 보다 효과적이고 휴대가 간편하며 사용하기 쉬운 광생체 자극기가 개발되고 있습니다. 이러한 기술 발전은 치료 효과를 향상시킬 뿐만 아니라 가정에서의 사용을 더욱 친숙하게 만들어 시장의 성장을 가져오고 있습니다.
광생체 자극기는 잠재적인 장점에도 불구하고 의료진과 소비자 모두 회의적인 시각으로 바라보고 있습니다. 특히 의료진과 환자들에게 새로운 기술을 사용하도록 설득하는 것은 어려운 일이며, 특히 이러한 기기의 작동 방식에 대한 인식과 이해가 부족한 경우에는 더욱 그렇다. 그 결과, 시장에 큰 장애물이 되고 있습니다.
광생체자극치료에 대한 보험 환급을 받는 것도 문제가 될 수 있습니다. 많은 보험사들은 비용 효과와 장기적인 혜택에 대한 강력한 증거가 없는 한 새로운 치료법이나 개발 중인 치료법을 받아들이는 데 신중한 태도를 보이고 있습니다. 따라서 일부 치료제의 경우 환자가 부담해야 하는 비용이 엄청나게 비싸기 때문에 환자들의 접근성이 제한될 수 있습니다.
또한, 미국 식품의약국(FDA), 유럽의약품청(EMA) 등 규제기관의 승인도 큰 장벽으로 작용하고 있습니다. 이러한 기기는 높은 안전성과 유효성 요건을 충족해야 하며, 승인 절차에 많은 시간과 비용이 소요됩니다.
The growing inclination toward non-invasive and drug-free therapeutic techniques is driven by increased awareness of their efficacy and safety, fueling demand for photobiostimulation devices. According to the analyst from Verified Market Research, the Photobiostimulation Devices Market is estimated to reach a valuation of USD 313.64 Million over the forecast subjugating aroundUSD 195.82 Million valued in 2023.
The market is gaining pace as healthcare professionals and consumers recognize the benefits of photobiostimulation therapy, resulting in increased usage of these devices in a variety of healthcare settings and enabling the market to grow at aCAGR of 6.07% from 2024 to 2031.
Photobiostimulation Devices Market: Definition/ Overview
Photobiostimulation devices, also known as low-level laser treatment (LLLT) or cold lasers, use certain wavelengths of light to activate cellular processes in the body. These devices produce non-thermal, low-intensity light that is absorbed by cells, resulting in a variety of biochemical responses that promote healing and tissue regeneration. In essence, photobiostimulation uses the therapeutic characteristics of light to accelerate the body's natural healing processes without causing harm.
Furthermore, these devices are utilized in a variety of medical and aesthetic disciplines. They are used in healthcare to control pain, reduce inflammation, and relieve musculoskeletal pain caused by illnesses such as arthritis, tendonitis, and sports injuries. Photobiostimulation devices are also used in wound healing to promote speedier recovery from both acute and chronic wounds, such as diabetic ulcers.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
The world's population is becoming more and more affected by chronic illnesses such as neuropathic pain, musculoskeletal disorders, and arthritis. As a result, photobiostimulation devices help manage pain, decrease inflammation, and encourage tissue healing in various situations, increasing the demand for such therapeutic options.
Non-invasive methods for pain management and rehabilitation have gained substantial traction among healthcare professionals and patients. This trend is supported by a rising amount of clinical evidence demonstrating the efficacy and safety of photobiostimulation therapy, contributing to its increasing adoption.
Furthermore, continuous advancements in laser and LED technology have resulted in the creation of more effective, portable, and user-friendly photobiostimulation devices. These technical advancements not only improve therapeutic efficacy but also make these devices more accessible for home use, hence growing the market.
Despite their potential benefits, photobiostimulation devices are viewed skeptically by both the medical establishment and consumers. Convincing healthcare providers and patients to use new technology is tough, especially when there is little awareness or comprehension of how these devices work. As a result, it acts as a significant obstacle for the market.
Obtaining insurance reimbursement for photobiostimulation therapies is possible to be problematic. Many insurance companies are cautious to accept novel or developing treatments unless there is strong evidence of their cost-effectiveness and long-term benefits. This limits patient access to these medicines because some treatments may be prohibitively expensive for some patients to pay out of pocket.
Furthermore, approval from regulatory organizations such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is a substantial barrier. These devices have to satisfy high safety and efficacy requirements, and the approval process can be lengthy and expensive.
According to VMR analysis, the infrared light segment is estimated to hold the largest market share in the type segment during the forecast period. Infrared light treatment is used for a variety of purposes, including pain relief, inflammation reduction, muscle repair, and wound healing. Its versatility appeals to a wide range of users, including medical professionals, physical therapists, and patients seeking at-home therapy choices. This diverse range of applications helps to explain the reason infrared light devices are more widely used than other types of photobiostimulation devices.
Infrared light penetrates deeper into tissues than red light or other forms of light utilized in photobiostimulation. This deeper penetration is critical for treating problems that occur in deeper layers of tissue, making infrared devices particularly beneficial for a wide range of medical and therapeutic applications, including muscle discomfort, joint issues, and certain types of chronic pain. The capacity to penetrate deeper tissues increases the utility and effectiveness of infrared photobiostimulation devices, contributing to their dominant market position.
Furthermore, infrared light therapy's efficacy and safety have been validated by extensive clinical evidence, resulting in regulatory approval for a wide range of medical and therapeutic applications. This robust clinical backing reassures both healthcare providers and patients, encouraging the use of infrared light equipment. Regulatory approvals also assist the introduction of these technologies into mainstream healthcare settings, increasing their market penetration.
The pain management segment is estimated to grow at the highest CAGR in the Photobiostimulation Devices Market during the forecast period. The rising prevalence of chronic pain diseases such as arthritis, back pain, and neck pain, among others, adds significantly to the demand for pain management solutions. Photobiostimulation devices provide a non-invasive, drug-free pain relief option that appeals to a diverse variety of individuals seeking alternatives to pharmaceutical pain management.
Photobiostimulation devices are becoming increasingly popular among healthcare practitioners for pain management. This is due to a substantial body of clinical evidence demonstrating their usefulness in pain management and tissue healing. As these devices become more integrated into normal pain management protocols, their market share in this segment is increasing.
Furthermore, technological improvements have improved the effectiveness, affordability, and accessibility of photobiostimulation devices. Innovations in device design, such as portability and ease of use, have allowed patients to utilize these devices at home, increasing their popularity for pain management.
According to VMR analyst, North America is estimated to dominate the Photobiostimulation Devices Market during the forecast period. North America is demonstrating an increasing preference for non-invasive treatment choices. Photobiostimulation devices, which offer a non-invasive technique for controlling chronic pain, wound healing, and cosmetic applications, connect well with this trend and are becoming increasingly popular in the region.
North America is home to several competitors in the market, contributing to the region's dominant position in the photobiostimulation device market. The region's inclination towards adopting technologically advanced, minimally invasive therapies promoting the development and use of photobiostimulation devices. The region's strong healthcare infrastructure and high healthcare expenditure support market growth.
Furthermore, the regulatory framework in North America, particularly in the United States, promotes innovation and speedy clearance of medical devices, including photobiostimulation devices. This environment stimulates companies to create and commercialise innovative and effective therapies, boosting market growth.
Asia Pacific is estimated to grow at the highest CAGR within the market during the forecast period. Asia Pacific has a large and expanding elderly population, making it more vulnerable to chronic illnesses that can be addressed using photobiostimulation devices, such as pain relief, wound treatment, and cosmetic applications. As these illnesses become more common, there is a greater need for photobiostimulation therapy.
Countries in Asia Pacific, particularly China and India, are experiencing significant economic expansion, resulting in higher healthcare spending. Such economic growth has increased access to healthcare services and modern medical technologies, such as photobiostimulation devices.
Furthermore, this region is experiencing an increase in the use of non-invasive treatments. Photobiostimulation devices are a non-invasive alternative to standard medical treatments for a range of illnesses, matching patient preferences and driving market expansion in the region.
The Photobiostimulation Devices Market is characterized by dynamic interactions between numerous companies competing for market share. Market companies are constantly striving to differentiate themselves by developing innovative photobiostimulation devices with improved efficacy, safety features, and usability.
Some of the prominent players operating in the Photobiostimulation Devices Market include:
Lumenis, BIOPTRON AG, PhotoMedex Inc., Zimmer Biomet, IRRAS, LiteCure LLC, Mettler Electronics Corp., TheraLight LLC, Quantum Devices Inc., Diomed Medical Group, Aktiia, BIOLUX, INTERNATIONAL CORP., CellGen Therapeutics, Cytalux Corporation, LED Medical Diagnostics Inc., LG Innotek, Koninklijke Philips N.V., MOSER BAER AG, PhotoSonix Medical Inc., and Verilux Inc.
In February 2024, BIOPTRON AG presented positive clinical data on the use of photobiostimulation treatment devices for wound healing at the Dubai World Dermatology Congress. The study discovered that the therapy dramatically decreased healing time while improving patient outcomes.
In February 2024, MOSER BAER announced an increase in its LED manufacturing capacity to accommodate the growing demand for photobiostimulation devices. This investment will allow the company to help its customers grow in this area.
In January 2024, PhotoMedex established a strategic agreement with Zimmer Biomet to develop and commercialise photobiostimulation devices for orthopaedic purposes. This alliance aims to harness both organisations' expertise to bring innovative ideas to market.
In October 2023, Philips announced a collaboration with the University of Amsterdam to investigate the use of photobiostimulation to treat brain problems. This collaboration seeks to investigate the potential of this technology for neurological applications.
In October 2023, Lumenis announced the Aculight(TM) Cynosure Laser System, a photobiostimulation therapy device to treat chronic pain and inflammation. The company says that the system has deeper tissue penetration and faster treatment times than previous models.